Relapsing polychondritis, an underestimated dermatological urgency: case report and literature review
No hay miniatura disponible
Fecha
2017
Título de la revista
Publicado en
International Journal of Dermatology, 1365-4632, Vol. 56, No. 12, 2017, p. 1379-1386
Publicado por
Wiley
URL de la fuente
ISSN de la revista
Título del volumen
Resumen
Descripción
Abstract
Relapsing polychondritis is an autoimmune multisystemic disease with primary chondral involvement. Its high mortality and morbidity make it a real clinical challenge.
A 32-year-old woman with a history of relapsing polychondritis, refractory to multiple treatments, with multisystem compromise, imminent risk of death due to severe tracheobronchial damage and difficult ventilatory support, and successful treatment with infliximab.
Several treatments have been described in the literature, such as nonsteroidal anti-inflammatory drugs, corticosteroids, dapsone, azathioprine, cyclosporine, cyclophosphamide, and methotrexate. However, the cases refractory to conventional therapy may lead to chronicity, irreversibility, and death. As a result, a third-line therapy could improve the prognosis of these patients.
Biological therapy is a good option for disease control and quality of life improvement. In addition, the physician should consider these treatments to avoid the chronicity and risk of death of these patients.
Palabras clave
Keywords
Adult, Dermatologic agents, Salvage therapy